--------------------
文献抄録 Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy/Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial) :a randomised controlled phase 2 trial.
荒川 芳輝
1
1京都大学脳神経外科
pp.985
発行日 2014年10月10日
Published Date 2014/10/10
DOI https://doi.org/10.11477/mf.1436200015
- フリーアクセス
- 1ページ目
Copyright © 2014, Igaku-Shoin Ltd. All rights reserved.